Shreeyashi Ojha is a journalist who writes for BioProcess International, covering topics related to the biopharmaceutical industry, including drug manufacturing, facility expansions, and acquisitions. Her work has also been featured in Asiana Times, where she has contributed articles on various subjects within the life sciences and healthcare sectors.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Shreeyashi Ojha's focus is on healthcare and pharmaceuticals, particularly on industry developments such as mergers, acquisitions, investments, and expansions. She primarily covers press releases and private sector announcements related to pharmaceutical companies' activities and strategic moves.
When reaching out to Shreeyashi or pitching her a story, it would be beneficial to provide insights into the latest happenings within major pharmaceutical companies, biotechnology firms or CDMOs (Contract Development and Manufacturing Organizations). Additionally, experts with knowledge of gene therapy advancements could offer valuable input for her articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Shreeyashi Ojha
The 250,000 square-foot site will house biosafety testing, analytical development, and cell-banking manufacturing services.
California-based biotechnology company Amgen is relocating its operations from Waterford to Dún Laoghaire, Ireland.
By: Shreeyashi Ojha
AGC Biologics confirms it has shut down “most operations” at its vacillating Longmont facility and is laying off 95 employees globally.
By: Shreeyashi Ojha
Drawing a roadmap on cell and gene therapy (CGT) markets, a panel of experts shed light on how investor behaviors and reimbursement practices are changing.
By: Shreeyashi Ojha
Veranova expands advisory board, while fellow contract development and manufacturing organizations (CDMO) get new CEOs. Welcome to the fortnightly roundup brought to you by BioProcess Insider.
By: Shreeyashi Ojha
Rentschler bolsters production with 3,400 square-meter expansion with new buffer media station at Germany site
The 8,000 square-meter facility is the first of the $7.6 billion Bio City project announced by Northway Healthcare Group.
By: Shreeyashi Ojha
The company has tripled manufacturing capacity of antibody drug conjugates (ADCs) at its facility in St. Louis, Missouri.
By: Shreeyashi Ojha
Pluri has collaborated with Bar-Ilan University to develop placental mucosal associated invariant (MAIT) T-cells for solid tumors. We spoke to the company’s spokesperson to find out more.
By: Shreeyashi Ojha
Ardena bolsters bioanalytical capacity with Netherlands lab construction
(833) 317-6278 
